Evommune Licenses EVO570 in $1.1 Billion Deal
The experimental oral drug targets VAV1 for autoimmune diseases under a licensing agreement with China's Hinova Pharmaceuticals.
Updated on Nov. 4, 2026 in Biotech
Evommune has licensed rights outside Greater China to EVO570, an experimental oral drug for autoimmune diseases, from Hinova Pharmaceuticals in a deal worth up to $1.1 billion. The agreement expands Evommune's pipeline of treatments for chronic inflammatory diseases.
Why it matters
The deal gives Evommune a potential entry into immunology research centered on VAV1, a target relevant to autoimmune conditions. It also reflects continued licensing activity between Chinese drug developers and Western biotech companies.
The licensing terms include a $30 million upfront payment, with $20 million in cash and $10 million in pre-funded warrants, against up to about $1.1 billion in milestone payments. Whether EVO570 will clear the development stages that trigger those payments has not been disclosed.
The players
Evommune
A California-based biotechnology company focused on developing treatments for chronic inflammatory diseases, which is expanding its pipeline through this licensing deal.
Hinova Pharmaceuticals
A Chengdu-based drug developer working on cancer, autoimmune and metabolic disease treatments, which markets a prostate cancer therapy in China.
The details
Under the agreement, Evommune gains rights outside Greater China to develop, manufacture and commercialize EVO570, an oral drug designed to treat autoimmune diseases by targeting VAV1. Hinova, based in Chengdu, is also eligible for tiered royalties on future sales and develops treatments for cancer, autoimmune and metabolic diseases.
Timeline
2027: Evommune plans to start a mid-stage study of EVO570 in rheumatoid arthritis.
Big Picture
The arrangement fits a recurring pattern in which Western biotechs license clinical-stage assets from Chinese developers, with rights carved out for Greater China. It positions Evommune within that cross-border licensing trend in immunology.
For patients with autoimmune conditions, this deal could eventually produce a new oral option, though the drug is still experimental and no approval timeline has been given. Nothing changes for patients today, as EVO570 remains in development.
The takeaway
Licensing deals like this one show how upfront payments are often small relative to contingent milestones, so the headline figure depends heavily on clinical progress. Readers tracking biotech should watch whether EVO570 advances into the planned 2027 mid-stage study.
What happens next
Evommune plans to start a mid-stage study of EVO570 in rheumatoid arthritis in 2027.
Further reading
Explore more on Biotech developments shaping drug licensing and pipelines worldwide.
